绥美凯治疗艾滋病有效果吗？

Therapeutic effects of AIDS:

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance. Suimeikai has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.

In the real world, antiviral therapy-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, Trimecaid, which uses DTG integrase inhibitors as its core, is controllable and effective in terms of drug safety and effectiveness.

At present, it has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Through effective treatment, the life span of AIDS patients and healthy people is getting closer and closer. Medication compliance and convenience of medication play an increasingly important role in further improving patients' quality of life. The approval of Suimeike has filled the gap in AIDS and met the urgent need for convenient medication for doctors and patients.

Recommended related hot articles: /newsDetail/71841.html